Interviews

Sarah Premji, MD, discusses recent advancements in the breast cancer treatment landscape.

Julie Brahmer, MD, and David P. Carbone, MD, PhD, share insights on managing toxicities of immune checkpoint inhibitor therapies in non–small cell lung cancer.

Dr Harpreet Singh discusses the FDA's new guidance on radiopharmaceutical dosing, emphasizing dose justification and data integration for patient safety.

Dr Harpreet Singh discusses the FDA's draft guidance on radiopharmaceutical dosing, highlighting significant shifts in dose limits and safety monitoring for clinical trials.

Harpreet Singh, MD, former FDA director, discusses the FDA's new draft guidance on radiopharmaceutical dosing and its relation to Project Optimus.

Innovative advancements in cell therapy enhance NK cells for solid tumors, aiming for effective treatments while prioritizing patient safety and clinical success.

Discover how El Camino Health's multidisciplinary approach enhances cancer care for younger adults, featuring collaboration among diverse medical specialists.

Gerrina Ruiter, MD, PhD, highlights the Beamion LUNG-1 study's impact on treating HER2-mutant non-small cell lung cancer with brain metastases.

Katy Rezvani, MD, PhD, discusses advancements in CAR-NK cell therapy, focusing on enhancing antitumor efficacy while ensuring safety through precise gene editing techniques.

Dr Sarah Premji discusses advancements in breast cancer treatment, emphasizing community trials, personalized therapies, and how to address unmet patient needs.

Dr Katy Rezvani reveals groundbreaking insights on enhancing CAR-NK cell therapy's effectiveness against solid tumors through innovative genetic strategies.

Katy Rezvani, MD, PhD, explores innovative CAR-NK cell therapies, highlighting their potential to overcome challenges in treating solid tumors and enhancing cancer treatment efficacy.

Andrew M. Brunner, MD, discusses the mechanism of action of telomerase inhibitors as treatment for anemia related to myelodysplastic syndrome.

Shane Dormady, MD, discusses the unique emotional care needs of young adults with cancer, emphasizing hope and holistic support for better outcomes.

Cancer care for younger adults emphasizes emotional well-being and multidisciplinary support, transforming treatment experiences and outcomes for this vulnerable group.

Discover how zipalertinib, an oral TKI, addresses unmet needs in treating EGFR exon 20 insertion-mutated non-small cell lung cancer.

Experts explore innovative therapies for high-risk smoldering multiple myeloma, aiming to delay progression and enhance patient outcomes through early intervention.

Michael Cole shares his decade-long battle with malignant pleural mesothelioma, highlighting treatment choices, resilience, and the vital doctor-patient relationship.

Paula Rodriguez Otero, MD, PhD, discusses promising results of linvoseltamab in high-risk smoldering multiple myeloma, highlighting its potential to prevent disease progression.

Paula Rodriguez Otero, MD, PhD, discusses linvoseltamab's manageable safety profile in high-risk smoldering multiple myeloma, highlighting promising study results.

Discover the latest advancements in lymphoma treatment, including innovative therapies and personalized medicine, enhancing patient outcomes and quality of life.

Prostate cancer advancements highlight genetic mutations' impact on therapy and family health, emphasizing early treatment strategies for better outcomes.

Experts explore the evolving treatment strategies for high-risk smoldering multiple myeloma, highlighting studies that show early intervention can improve patient outcomes.

Research explores innovative treatments for high-risk smoldering multiple myeloma, highlighting promising results from the bispecific antibody linvoseltamab.

Dr Daniel Petrylak discusses groundbreaking advancements in prostate cancer treatment, including genetic mutations, PARP inhibitors, and innovative PROTAC therapies.

New findings reveal tarlatamab combined with anti–PD-L1 agents significantly improves survival in extensive-stage small cell lung cancer, prompting further research.

Dr Kelly Paulson shares groundbreaking insights from the DeLLphi-303 study, highlighting new immunotherapy strategies for small cell lung cancer treatment.

Discover groundbreaking advancements in prostate cancer treatment with innovative PROTAC drugs, promising new trials, and enhanced therapy effectiveness.

Navigating the complex landscape of prostate cancer treatment sequencing is crucial for maximizing patient outcomes and survival rates.

Andrew Jallouk, MD, discusses the surge of approved therapies in lymphoma over the past decade.